We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Optimata to Collaborate with Teva Pharmaceutical on Clinical Development of Solid Tumor Cancer Drugs
News

Optimata to Collaborate with Teva Pharmaceutical on Clinical Development of Solid Tumor Cancer Drugs

Optimata to Collaborate with Teva Pharmaceutical on Clinical Development of Solid Tumor Cancer Drugs
News

Optimata to Collaborate with Teva Pharmaceutical on Clinical Development of Solid Tumor Cancer Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Optimata to Collaborate with Teva Pharmaceutical on Clinical Development of Solid Tumor Cancer Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Optimata Ltd. has announced that it has signed a collaboration agreement with Teva Pharmaceutical Industries Ltd. focused on clinical development of drug candidates for solid tumor cancers.

The agreement is intended to rescue and redirect the clinical development of discontinued drug candidates which have been shelved by their originators pharmaceutical companies, using Optimata’s bio-simulation technology known as the Optimata Virtual Patient® (OVP).

Under the terms of the collaboration, Optimata will receive upfront payments, development milestones and royalty payments; in a separate agreement, Teva Pharmaceutical Industries Ltd. has also made an undisclosed equity investment in Optimata Ltd.

Dr. Pini Orbach, COO of Optimata, commented: “Having Teva Pharmaceutical Industries Ltd. as a partner is clearly a transforming event in the history of our company. With this new collaboration we continue to fulfill Optimata’s goal of accelerating the oncology drug development process”.
Advertisement